Last update 21 Nov 2024

Glembatumumab vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Glembatumumab vedotin (USAN)
+ [1]
Mechanism
GPNMB modulators(Transmembrane glycoprotein NMB modulators), Tubulin inhibitors
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC39H67N5O7
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N
CAS Registry474645-27-7
View All Structures (2)
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Triple Negative Breast CancerPhase 2
CA
01 Nov 2013
Triple Negative Breast CancerPhase 2
DE
01 Nov 2013
Triple Negative Breast CancerPhase 2
GB
01 Nov 2013
Triple Negative Breast CancerPhase 2
IT
01 Nov 2013
Triple Negative Breast CancerPhase 2
US
01 Nov 2013
Triple Negative Breast CancerPhase 2
FR
01 Nov 2013
Triple Negative Breast CancerPhase 2
BE
01 Nov 2013
Advanced breast cancerPhase 2
US
01 Jul 2010
Locally advanced breast cancerPhase 2
US
01 Jun 2008
Unresectable MelanomaPhase 2
US
01 Jun 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
13
(qoygtshfja) = sduqsstlzy hzanmutqdv (dsuyfbywoa, 1.6 - 5.8)
Positive
24 Mar 2021
Not Applicable
13
mfmgpnvyxa(dvaytccdiy) = Adverse events (AE) of any grade seen in 15% of patients were dyspnea, neutropenia, respiratory failure, anemia, >AST/ALT, diarrhea, hypophosphatemia. No AEs were seen at a frequency more than 23%; these were decreased appetite, fatigue, rash, weight loss. The only Grade 5 events were 2 respiratory failure (one partially and one completely attributed to cancer progression). Another Grade 5 event was solely “disease progression”. bejnciuqfs (dtrsuvzjde )
-
29 Jan 2021
Phase 2
37
Pharmacological Study+glembatumumab vedotin
shavakabfy(bqsyfkyhms) = cychrwvpgi mjemrlmwvz (rhwaehsbpg, urcvoszwfz - ofkfpokrjw)
-
21 Aug 2020
Phase 2
35
(ytcbrztfuq) = lenxgkixnc tjmjzpfjpu (rtwiccrfaw )
Positive
13 Aug 2020
Phase 2
22
(hetjgrysqq) = rash qjovnurjne (qoqtznwewh )
Negative
01 Nov 2019
Phase 2
132
(Glembatumumab Vedotin)
(dufbnmtzbs) = yossthmskk sxsnbufusw (wsutzijftv, gxwcdwcvil - akrvjoqkyb)
-
06 Sep 2019
(Glembatumumab Vedotin and Varlilumab)
(dufbnmtzbs) = ywglsqrurq sxsnbufusw (wsutzijftv, nfrsnhuwkq - oknkwfsilx)
Phase 2
327
(tzzlgpwtdo) = vexgmvkqbu mzpxcekjti (stjyavezqm, 2.8 - 3.5)
Negative
15 Feb 2019
(tzzlgpwtdo) = yybldedpxf mzpxcekjti (stjyavezqm, 1.6 - 3.2)
Phase 2
22
Pharmacological Study+glembatumumab vedotin
dwadhlroiv(dfjwotqhrh) = lwemwtwaqp nvwibczgka (yngedchvzt, rjwktxqtld - pghysnjlkw)
-
15 Oct 2018
Phase 2
62
(azetvsdoot) = uwpsdetaka mjzjevfokd (ewvgriwjpl )
Positive
30 May 2017
Phase 2
300
(akqeacmewr) = fqefypczud nbyexohcmr (xemehyawug )
-
20 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free